Capítulo 1. Generalidades de la Enfermedad de Parkinson

TOLOSA E, WENNING G, POEWE W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006; 5:75-86.

PEARCE J. M. Aspects of the history of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1986; Suppl: 6-10.

OLANOW CW. The pathogenesis of cell death in Parkinson’s disease— 2007. Mov Disord. 2007; 22 Suppl 17: S335-42.

SÁNCHEZ JL, BURITICÁ O, PINEDA D, URIBE CS, PALACIO LG. Prevalence of Parkinson’s disease and parkinsonism in a Colombian population using the capture-recapture method. Int J Neurosci. 2004;114(2): 175-82.

PRADILLA G, VESGA B, LEÓN-SARMIENTO F, GRUPO GENECO. Estudio neuroepidemiológico nacional (EPINEURO) colombiano. Rev Panam Salud Publica. 2003 Aug;14(2): 104-11.

DE LAU LM, BRETELER M. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006; 5: 525-35.

ALLAM MF, NAVAJAS R, DEL CASTILLO AS. Factores de riesgo en la enfermedad de Parkinson. Revista de Neurología. 2003; 36(8): 749.

MOLINA JA, BERBEL A, PORTA J. EP: clínica y diagnóstico. In: Jiménez FJ, Luquin MR, Molina JA (eds.). Tratado de trastornos del movimiento. Madrid; 1999:279-301.

HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’disease. A clínico-pathologycal study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 1992; 55: 181-184.

NANDHAGOPAL R, MCKEOWN MJ, STOESSL AJ. Functional imaging in Parkinson’s disease. Neurology. 2008; 70: 1478-88.

SCHERFLER, C, SCHWARZ J, ANTONINI A, GROSSET D, VALLDEORIOLA F, MAREK K, ET AL. Role in DAT SPECT in the diagnostic work up of parkinsonism. MO Disord. 2007; 22: 1229-38.

EEROLA J, TIENARI PJ, KAAKKOLA S, NIKKINEN P, LAUNES J. How useful is (123I)b-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry. 2005; 76: 1211-6.

JENNINGS DL, SEIBYL JP, OAKES D, EBERLY S, MURPHY J, MAREK K. (123I)-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in parkinsonian syndrome. Arch Neurol. 2004; 61: 1224-9.

BROOKS DJ. Neuroimaging in Parkinson’s disease. NeuroRx. 2004; 1: 243-54.

SPIEGEL J, MÖLLERS MO, JOST WH, FUSS G, SAMNICK S, DILLMAN U, ET AL. FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov Disord. 2005; 20:552-61.

BERG D, SIEFKER C, BECKER G. Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol. 2001;248:684-9.

WALTER U, NIEHAUS L, PROBST T, BENECKE R, MEYER BU, DRESSLER D. Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes. Neurology. 2003; 60: 74-7.

HOEHN MM, YAHR MD. Parkinsonism: onset, progression and mortality. Neurology. 1967; 17: 427-42.

GOETZ CG, POEWE W, RASCOL O, SAMPAIO C, STEBBINS GT, COUNSELL C, ET AL. Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: status and recommendations. Mov Disord. 2004; 19:1020-8.

SCHWAB RS, ENGLAND AC. Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson’s disease. Edinburgh: E. and S. Livingstone; 1969. p. 152-7.

MCRAE C, DIEM G, VO A, O’BRIEN C, SEEBERGER L. Schwab & England: stan- dardization of administration. Mov Disord. 2000; 15: 335-6.

GOETZ CG, FAHN S, MARTINEZ-MARTIN P, POEWE W, SAMPAIO C, STEBBINS GT, ET AL. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007; 22: 41-7.

CHAUDHURI KR, MARTINEZ-MARTIN P, SCHAPIRA AH, STOCCHI F, SETHI K, ODIN P, ET AL. International multicenter pilot study of the first comprehensive self-com- pleted nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006; 21:916-23.